Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$240.71+0.94 (+0.39%)
Close on Nov 17, 2026Market cap $15.63BP/E 78.4Yield –
Jazz Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Jazz Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was $1.69B, up 21.6% year over year. For fiscal 2025 it was $1.36B, down 2.9% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $1.40B in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | -2.9% |
| FY2024 | Dec 31, 2024 | $1.40B | +27.8% |
| FY2023 | Dec 31, 2023 | $1.09B | -14.1% |
| FY2022 | Dec 31, 2022 | $1.27B | +63.4% |
| FY2021 | Dec 31, 2021 | $778.51M | -13.5% |
| FY2020 | Dec 31, 2020 | $899.65M | +15.9% |
| FY2019 | Dec 31, 2019 | $776.40M | -2.8% |
| FY2018 | Dec 31, 2018 | $798.90M | +15.3% |
| FY2017 | Dec 31, 2017 | $693.09M | +17.0% |
| FY2016 | Dec 31, 2016 | $592.39M | +11.4% |
| FY2015 | Dec 31, 2015 | $531.94M | +30.5% |
| FY2014 | Dec 31, 2014 | $407.61M | +41.3% |
| FY2013 | Dec 31, 2013 | $288.43M | +15.5% |
| FY2012 | Dec 31, 2012 | $249.75M | +64.7% |
| FY2011 | Dec 31, 2011 | $151.60M | +157.5% |
| FY2010 | Dec 31, 2010 | $58.87M | – |
| FY2009 | Dec 31, 2009 | -$15.88M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $506.10M | +6.6% |
| Q2 FY2026 | Jun 30, 2026 | $415.70M | +368.1% |
| Q1 FY2026 | Mar 31, 2026 | $408.20M | -5.0% |
| Q4 FY2025 | Dec 31, 2025 | $362.47M | -9.1% |
| Q3 FY2025 | Sep 30, 2025 | $474.70M | +19.0% |
| Q2 FY2025 | Jun 30, 2025 | $88.80M | -73.2% |
| Q1 FY2025 | Mar 31, 2025 | $429.80M | +60.8% |
| Q4 FY2024 | Dec 31, 2024 | $398.58M | +138.2% |
| Q3 FY2024 | Sep 30, 2024 | $398.75M | +29.8% |
| Q2 FY2024 | Jun 30, 2024 | $331.35M | +11.7% |
| Q1 FY2024 | Mar 31, 2024 | $267.23M | -16.7% |
| Q4 FY2023 | Dec 31, 2023 | $167.34M | -51.1% |
| Q3 FY2023 | Sep 30, 2023 | $307.20M | -26.5% |
| Q2 FY2023 | Jun 30, 2023 | $296.77M | -2.1% |
| Q1 FY2023 | Mar 31, 2023 | $320.71M | +53.5% |
| Q4 FY2022 | Dec 31, 2022 | $341.97M | +92.4% |
| Q3 FY2022 | Sep 30, 2022 | $417.99M | +52.5% |
| Q2 FY2022 | Jun 30, 2022 | $303.04M | +626.8% |
| Q1 FY2022 | Mar 31, 2022 | $208.98M | -26.7% |
| Q4 FY2021 | Dec 31, 2021 | $177.76M | -4.6% |
| Q3 FY2021 | Sep 30, 2021 | $274.06M | +6.3% |
| Q2 FY2021 | Jun 30, 2021 | $41.70M | -77.2% |
| Q1 FY2021 | Mar 31, 2021 | $285.00M | +4.4% |
| Q4 FY2020 | Dec 31, 2020 | $186.27M | +112.2% |
| Q3 FY2020 | Sep 30, 2020 | $257.89M | -23.6% |
| Q2 FY2020 | Jun 30, 2020 | $182.52M | +22.6% |
| Q1 FY2020 | Mar 31, 2020 | $272.97M | +35.0% |
| Q4 FY2019 | Dec 31, 2019 | $87.80M | -59.7% |
| Q3 FY2019 | Sep 30, 2019 | $337.50M | +52.4% |
| Q2 FY2019 | Jun 30, 2019 | $148.85M | -22.5% |
| Q1 FY2019 | Mar 31, 2019 | $202.25M | +20.8% |
| Q4 FY2018 | Dec 31, 2018 | $218.10M | +6.6% |
| Q3 FY2018 | Sep 30, 2018 | $221.48M | +17.2% |
| Q2 FY2018 | Jun 30, 2018 | $191.97M | +42.1% |
| Q1 FY2018 | Mar 31, 2018 | $167.36M | +1.7% |
| Q4 FY2017 | Dec 31, 2017 | $204.56M | +13.2% |
| Q3 FY2017 | Sep 30, 2017 | $188.90M | – |
| Q2 FY2017 | Jun 30, 2017 | $135.09M | – |
| Q1 FY2017 | Mar 31, 2017 | $164.54M | – |
| Q4 FY2016 | Dec 31, 2016 | $180.70M | – |
See a number that looks wrong?